BOSTON and LAUSANNE,
Switzerland, June 14, 2022 /PRNewswire/ -- SOPHiA GENETICS
(Nasdaq: SOPH), a leader in data-driven medicine, today announced
from the ESHG Conference in Vienna
that it has achieved CE-IVD certification for the analytical
functionality supported by its cloud-based SOPHiA DDM™ Platform, an
accessory to diagnostic applications. With this certification,
the SOPHiA DDM™ Platform is now IVD-ready to support all
applications and modules designed for diagnostic purposes in the
European Union and other markets recognizing this
certification.
The SOPHiA DDM™ Platform has already facilitated the analysis of
one million genomic profiles; today, it becomes a core platform for
partners from the healthcare and biopharma industry to run their
applications, benefitting from a regulated space and a
decentralized access mode, while leveraging the reach of the SOPHiA
Community. Powered by the Company's proprietary deep learning
algorithms, the SOPHiA DDM™ Platform supports state-of-art oncology
technologies, including five CE-IVD SOPHiA DDM applications,
including the newly registered SOPHiA DDM™ Dx Homologous
Recombination Deficiency (HRD) Solution and SOPHiA
DDM™ Dx RNAtarget Oncology Solution.
"We started SOPHiA GENETICS with a mission to be the global
platform that allows healthcare professionals to leverage their
expertise and work together around the world – unlocking the
promise of data-driven medicine at scale," said Dr. Jurgi Camblong,
co-founder and CEO at SOPHiA GENETICS. "The CE-IVD certification
for these IVD applications is a milestone that reflects the quality
and reliability of our SOPHiA DDM™ Platform. This will help us meet
the needs of our healthcare partners in the EU who want to
implement SOPHiA GENETICS' proprietary algorithms for clinical
use."
Supporting the CE-IVD certifications using the SOPHiA DDM™
Platform demonstrates the commitment of SOPHiA GENETICS in
maintaining a firm focus on delivering accurate and reliable
solutions to more than 790 leading healthcare institutions across
the world. The SOPHiA DDM™ Platform, leverages on the collective
intelligence gathered by SOPHiA GENETICS' global network of
connected partners. Healthcare professionals can confidently adopt
standardized data-driven medicine applications as part of their
routine workflow in the EU, for the benefit of patients all over
the world.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a health care technology company dedicated to establishing the
practice of data-driven medicine as the standard of care and for
life sciences research. It is the creator of the SOPHiA DDM™
Platform, a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and related
solutions, products and services are currently used by more than
790 hospital, laboratory, and biopharma institutions globally. For
more information, visit SOPHiAGENETICS.COM, or connect on Twitter,
LinkedIn and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this press release speak only as of the
date hereof. We expressly disclaim any obligation or undertaking to
update these forward-looking statements contained in this press
release to reflect any change in our expectations or any change in
events, conditions, or circumstances on which such statements are
based, unless required to do so by applicable law. No
representations or warranties (expressed or implied) are made about
the accuracy of any such forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg